Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Redx Pharma’s Porcupine inhibitor touted for potential to tackle hard-to-treat cancers
October 27, 2016
By: Tim Wright
Editor-in-Chief, Contract Pharma
Contract development, manufacturing and packaging organization, Quay Pharma, has entered into an agreement with drug discovery and development company, Redx Pharma, to manufacture its new cancer treatment drug. The new Porcupine inhibitor has the potential to tackle hard-to-treat cancers such as pancreatic, gastric and biliary. Quay will formulate the capsules, which will be administered during the drug’s first-in-human studies early 2017. The new treatment will have the potential for patients to take it orally as a once-daily dose. The inhibitor targets an embryonic signaling pathway that assists maintaining cancer stem cells associated with tumorigenesis, metastasis, recurrence and resistance. “We are delighted that Redx has selected Quay Pharma based upon our formulation development expertise, unparalleled flexibility and successful track record of delivering clinical trial supplies on time,” said Maireadh Pedersen, chief executive officer, Quay Pharma. Neil Murray, chief executive officer, Redx Pharma, said, “Less than 10% of pancreatic cancer patients survive five years from their diagnosis. The potential for this new class of drugs to tackle some of these difficult cancers could see a significant advance for patients who have few meaningful treatment options today. Our Porcupine inhibitor is an especially exciting clinical candidate, both scientifically and commercially. We are pleased to confirm that we remain on track to enter the clinical trial phase early 2017.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !